Y
Yasushi Yatabe
Researcher at Nagoya University
Publications - 692
Citations - 55166
Yasushi Yatabe is an academic researcher from Nagoya University. The author has contributed to research in topics: Lung cancer & Cancer. The author has an hindex of 96, co-authored 630 publications receiving 48049 citations. Previous affiliations of Yasushi Yatabe include University of Southern California & Gunma University.
Papers
More filters
Journal ArticleDOI
International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma
William D. Travis,Elisabeth Brambilla,Masayuki Noguchi,Andrew G. Nicholson,Kim R. Geisinger,Yasushi Yatabe,David G. Beer,Charles A. Powell,Gregory J. Riely,Paul Van Schil,Kavita Garg,John H. M. Austin,Hisao Asamura,Valerie W. Rusch,Fred R. Hirsch,Giorgio V. Scagliotti,Tetsuya Mitsudomi,Rudolf M. Huber,Yuichi Ishikawa,James R. Jett,Montserrat Sanchez-Cespedes,Jean-Paul Sculier,Takashi Takahashi,Masahiro Tsuboi,Johan Vansteenkiste,Ignacio I. Wistuba,Pan-Chyr Yang,Denise R. Aberle,Christian Brambilla,Douglas B. Flieder,Wilbur A. Franklin,Adi F. Gazdar,Michael K. Gould,Philip S. Hasleton,Douglas W. Henderson,Bruce E. Johnson,David A Johnson,Keith M. Kerr,Keiko Kuriyama,Jin Soo Lee,Vincent A. Miller,Iver Petersen,Victor L. Roggli,Rafael Rosell,Nagahiro Saijo,Erik Thunnissen,M. Tsao,David Yankelewitz +47 more
TL;DR: This new adenocarcinoma classification is needed to provide uniform terminology and diagnostic criteria, especially for bronchioloalveolar carcinoma (BAC), the overall approach to small nonresection cancer specimens, and for multidisciplinary strategic management of tissue for molecular and immunohistochemical studies.
Journal ArticleDOI
Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial
Tetsuya Mitsudomi,Satoshi Morita,Yasushi Yatabe,Shunichi Negoro,Isamu Okamoto,Junji Tsurutani,Takashi Seto,Miyako Satouchi,Hirohito Tada,Tomonori Hirashima,Kazuhiro Asami,Nobuyuki Katakami,Minoru Takada,Hiroshige Yoshioka,Kazuhiko Shibata,Shinzoh Kudoh,Eiji Shimizu,Hiroshi Saito,Shinichi Toyooka,Kazuhiko Nakagawa,Masahiro Fukuoka +20 more
TL;DR: In this article, an open label, phase 3 study (WJTOG3405) with recruitment between March 31, 2006, and June 22, 2009, at 36 centers in Japan was conducted.
Journal ArticleDOI
The 2015 World Health Organization Classification of Lung Tumors: Impact of Genetic, Clinical and Radiologic Advances Since the 2004 Classification
William D. Travis,Elisabeth Brambilla,Andrew G. Nicholson,Yasushi Yatabe,John H.M. Austin,Mary Beth Beasley,Lucian R. Chirieac,Sanja Dacic,Edwina Duhig,Douglas B. Flieder,Kim R. Geisinger,Fred R. Hirsch,Yuichi Ishikawa,Keith M. Kerr,Masayuki Noguchi,Giuseppe Pelosi,Charles A. Powell,Ming-Sound Tsao,Ignacio I. Wistuba +18 more
TL;DR: The 2015 World Health Organization (WHO) Classification of Tumors of the Lung, Pleura, Thymus and Heart has just been published with numerous important changes from the 2004 WHO classification.
Journal ArticleDOI
Reduced Expression of the let-7 MicroRNAs in Human Lung Cancers in Association with Shortened Postoperative Survival
Junichi Takamizawa,Hiroyuki Konishi,Kiyoshi Yanagisawa,Shuta Tomida,Hirotaka Osada,Hideki Endoh,Tomoko Harano,Yasushi Yatabe,Masato Nagino,Yuji Nimura,Tetsuya Mitsudomi,Takashi Takahashi +11 more
TL;DR: Reduced expression of let-7 in A549 lung adenocarcinoma cell line inhibited lung cancer cell growth in vitro and represents the first report of reduced expression ofLet-7 and the potential clinical and biological effects of such a microRNA alteration.
Journal ArticleDOI
A Polycistronic MicroRNA Cluster, miR-17-92, Is Overexpressed in Human Lung Cancers and Enhances Cell Proliferation
Yoji Hayashita,Hirotaka Osada,Yoshio Tatematsu,Hideki Yamada,Kiyoshi Yanagisawa,Shuta Tomida,Yasushi Yatabe,Katsunobu Kawahara,Yoshitaka Sekido,Takashi Takahashi +9 more
TL;DR: Findings clearly suggest that marked overexpression of the miR-17-92 cluster with occasional gene amplification may play a role in the development of lung cancers, especially in their most aggressive form, small-cell lung cancer, and that the C13orf25 gene may well be serving as a vehicle in this regard.